Isoproterenol induced hypertrophy and associated signaling pathways are modulated by Somatostatin in H9c2 cells

International Journal of Cardiology

Volumn 167, Issue 3, 2013, Pages 1012-1022

  Somvanshi, Rishi K ^a   Qiu, Xiaofan ^a   Kumar, Ujendra ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Adrenergic receptor; Cardiomyocytes; Hypertrophy; MAP kinase; Somatostatin

Indexed keywords

4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; FORMOTEROL; ISOPRENALINE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; SOMATOSTATIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL LEVEL; CELL PROTECTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; FETUS; HEART MUSCLE CELL; HORMONE ACTION; IMMUNOCYTOCHEMISTRY; MUSCLE HYPERTROPHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ADRENERGIC RECEPTOR; CARDIOMYOCYTES; HYPERTROPHY; MAP KINASE; SOMATOSTATIN;

ANIMALS; CARDIOMEGALY; CELL LINE; ISOPROTERENOL; MYOCYTES, CARDIAC; RATS; SIGNAL TRANSDUCTION; SOMATOSTATIN;

EID: 84880920551     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.03.077     Document Type: Article

References (80)

1. U. Kumar, and M. Grant J. Rehfeld, J. Bundgaard, Somatostatin and somatostatin receptors Results Probl Cell Differ 2010 137 184
2. Y.C. Patel Somatostatin and its receptor family Front Neuroendocrinol 20 1999 157 198
3. E.T. Janson, and K. Oberg Somatostatin receptor ligands and their use in the treatment of endocrine disorders Curr Pharm Des 5 1999 693 705
4. B.O. Boehm The therapeutic potential of somatostatin receptor ligands in the treatment of obesity and diabetes Expert Opin Investig Drugs 12 2003 1501 1509
5. W.W. de Herder, A.J. van der Lely, and S.W. Lamberts Somatostatin analogue treatment of neuroendocrine tumours Postgrad Med J 72 1996 403 408
6. S.W. Lamberts, W.W. de Herder, and P.M. van Koetsveld Somatostatin receptors: clinical implications for endocrinology and oncology Ciba Found Symp 190 1995 222 236 discussion 36-9
7. J. Wahren Influence of somatostatin on carbohydrate disposal and absorption in diabetes mellitus Lancet 2 1976 1213 1216
8. E.A. Woltering, R. Barrie, and T.M. O'Dorisio Somatostatin analogues inhibit angiogenesis in the chick chorioallantoic membrane J Surg Res 50 1991 245 251
9. D. Bell, Y. Zhao, and B. McMaster SRIF receptor subtype expression and involvement in positive and negative contractile effects of somatostatin-14 (SRIF-14) in ventricular cardiomyocytes Cell Physiol Biochem 22 2008 653 664
10. F. Murray, D. Bell, E.J. Kelso, B.C. Millar, and B.J. McDermott Positive and negative contractile effects of somatostatin-14 on rat ventricular cardiomyocytes J Cardiovasc Pharmacol 37 2001 324 332
11. Y.C. Patel, and C.B. Srikant Somatostatin receptors Trends Endocrinol Metab 8 1997 398 405
12. P. Hayry, A. Raisanen, J. Ustinov, A. Mennander, and T. Paavonen Somatostatin analog lanreotide inhibits myocyte replication and several growth factors in allograft arteriosclerosis FASEB J 7 1993 1055 1060
13. K. Yumi, J.A. Fagin, and M. Yamashita Direct effects of somatostatin analog octreotide on insulin-like growth factor-I in the arterial wall Lab Invest 76 1997 329 338
14. W.H. Smith, R.U. Nair, D. Adamson, M.T. Kearney, S.G. Ball, and A.J. Balmforth Somatostatin receptor subtype expression in the human heart: differential expression by myocytes and fibroblasts J Endocrinol 187 2005 379 386
15. R. Granata, L. Trovato, S. Destefanis, F. Settanni, and E. Ghigo H9c2 cardiac muscle cells express all somatostatin receptor subtypes J Endocrinol Invest 27 2004 RC24 RC27
16. J.F. Bruno, Y. Xu, J. Song, and M. Berelowitz Tissue distribution of somatostatin receptor subtype messenger ribonucleic acid in the rat Endocrinology 133 1993 2561 2567
17. A. Ben-Shlomo, and S. Melmed Pituitary somatostatin receptor signaling Trends Endocrinol Metab 21 2010 123 133
18. J.J. Tentler, J.R. Hadcock, and A. Gutierrez-Hartmann Somatostatin acts by inhibiting the cyclic 3′,5′-adenosine monophosphate (cAMP)/protein kinase A pathway, cAMP response element-binding protein (CREB) phosphorylation, and CREB transcription potency Mol Endocrinol 11 1997 859 866
19. N. Dzimiri Regulation of beta-adrenoceptor signaling in cardiac function and disease Pharmacol Rev 51 1999 465 501
20. H. Tong, D. Bernstein, E. Murphy, and C. Steenbergen The role of beta-adrenergic receptor signaling in cardioprotection FASEB J 19 2005 983 985
21. D. Bernstein, G. Fajardo, and M. Zhao Differential cardioprotective/ cardiotoxic effects mediated by beta-adrenergic receptor subtypes Am J Physiol Heart Circ Physiol 289 2005 H2441 H2449
22. T. Ichiki Role of cAMP response element binding protein in cardiovascular remodeling: good, bad, or both? Arterioscler Thromb Vasc Biol 26 2006 449 455
23. V.O. Nikolaev, A. Moshkov, and A.R. Lyon Beta2-adrenergic receptor redistribution in heart failure changes cAMP compartmentation Science 327 2010 1653 1657
24. C. Communal, W.S. Colucci, and K. Singh p38 mitogen-activated protein kinase pathway protects adult rat ventricular myocytes against beta-adrenergic receptor-stimulated apoptosis. Evidence for Gi-dependent activation J Biol Chem 275 2000 19395 19400
25. X. Lu, S. Nemoto, and A. Lin Identification of c-Jun NH2-terminal protein kinase (JNK)-activating kinase 2 as an activator of JNK but not p38 J Biol Chem 272 1997 24751 24754
26. D.S. Nagarkatti, and R.I. Sha'afi Role of p38 MAP kinase in myocardial stress J Mol Cell Cardiol 30 1998 1651 1664
27. P.S. Peter, J.E. Brady, and L. Yan Inhibition of p38 alpha MAPK rescues cardiomyopathy induced by overexpressed beta 2-adrenergic receptor, but not beta 1-adrenergic receptor J Clin Invest 117 2007 1335 1343
28. P.M. Holland, M. Suzanne, J.S. Campbell, S. Noselli, and J.A. Cooper MKK7 is a stress-activated mitogen-activated protein kinase kinase functionally related to hemipterous J Biol Chem 272 1997 24994 24998
29. C. Tournier, A.J. Whitmarsh, J. Cavanagh, T. Barrett, and R.J. Davis Mitogen-activated protein kinase kinase 7 is an activator of the c-Jun NH2-terminal kinase Proc Natl Acad Sci U S A 94 1997 7337 7342
30. N.C. Salazar, J. Chen, and H.A. Rockman Cardiac GPCRs: GPCR signaling in healthy and failing hearts Biochim Biophys Acta 1768 2007 1006 1018
31. S.L. Tokgozoglu, T. Erbas, K. Aytemir, S. Akalin, S. Kes, and E. Oram Effects of octreotide on left ventricular mass in acromegaly Am J Cardiol 74 1994 1072 1074
32. M.J. Lim, A.L. Barkan, and A.J. Buda Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion Ann Intern Med 117 1992 719 726
33. A. Colao, A. Cuocolo, and P. Marzullo Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance J Clin Endocrinol Metab 86 2001 1551 1557
34. R. Baldelli, E. Ferretti, and M.L. Jaffrain-Rea Cardiac effects of slow-release lanreotide, a slow-release somatostatin analog, in acromegalic patients J Clin Endocrinol Metab 84 1999 527 532
35. F. Manelli, P. Desenzani, and E. Boni Cardiovascular effects of a single slow release lanreotide injection in patients with acromegaly and left ventricular hypertrophy Pituitary 2 1999 205 210
36. R.K. Somvanshi, N. Chaudhari, X. Qiu, and U. Kumar Heterodimerization of beta2 adrenergic receptor and somatostatin receptor 5: implications in modulation of signaling pathway J Mol Signaling 6 2011 9
37. R.K. Somvanshi, S.A. War, N. Chaudhari, X. Qiu, and U. Kumar Receptor specific crosstalk and modulation of signaling upon heterodimerization between beta1-adrenergic receptor and somatostatin receptor-5 Cell Signal 23 2011 794 811
38. V. Dangel, J. Giray, D. Ratge, and H. Wisser Regulation of beta-adrenoceptor density and mRNA levels in the rat heart cell-line H9c2 Biochem J 317 Pt 3 1996 925 931
39. E. Dick, D. Rajamohan, J. Ronksley, and C. Denning Evaluating the utility of cardiomyocytes from human pluripotent stem cells for drug screening Biochem Soc Trans 38 2010 1037 1045
40. S.J. Watkins, G.M. Borthwick, and H.M. Arthur The H9C2 cell line and primary neonatal cardiomyocyte cells show similar hypertrophic responses in vitro In Vitro Cell Dev Biol Anim 47 2011 125 131
41. K. Jeong, H. Kwon, C. Min, and Y. Pak Modulation of the caveolin-3 localization to caveolae and STAT3 to mitochondria by catecholamine-induced cardiac hypertrophy in H9c2 cardiomyoblasts Exp Mol Med 41 2009 226 235
42. R.K. Somvanshi, S. Billova, G. Kharmate, P.S. Rajput, and U. Kumar C-tail mediated modulation of somatostatin receptor type-4 homo- and heterodimerizations and signaling Cell Signal 21 2009 1396 1414
43. A. Colao, A. Cuocolo, and P. Marzullo Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly J Clin Endocrinol Metab 84 1999 17 23
44. A. Colao, P. Marzullo, and D. Ferone Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly J Clin Endocrinol Metab 85 2000 3132 3140
45. B. Merola, A. Cittadini, and A. Colao Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly J Clin Endocrinol Metab 77 1993 790 793
46. N. Frey, and E.N. Olson Cardiac hypertrophy: the good, the bad, and the ugly Annu Rev Physiol 65 2003 45 79
47. M.P. Delghandi, M. Johannessen, and U. Moens The cAMP signalling pathway activates CREB through PKA, p38 and MSK1 in NIH 3T3 cells Cell Signal 17 2005 1343 1351
48. J.C. Braz, O.F. Bueno, and Q. Liang Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling J Clin Invest 111 2003 1475 1486
49. V. Casado, A. Cortes, and J. Mallol GPCR homomers and heteromers: a better choice as targets for drug development than GPCR monomers? Pharmacol Ther 124 2009 248 257
50. B.J. Maron Hypertrophic cardiomyopathy Lancet 350 1997 127 133
51. A. Colao, P. Marzullo, C. Di Somma, and G. Lombardi Growth hormone and the heart Clin Endocrinol (Oxf) 54 2001 137 154
52. L. Thuesen, S.E. Christensen, J. Weeke, H. Orskov, and P. Henningsen The cardiovascular effects of octreotide treatment in acromegaly: an echocardiographic study Clin Endocrinol (Oxf) 30 1989 619 625
53. C. Petrucci, D. Cervia, M. Buzzi, C. Biondi, and P. Bagnoli Somatostatin-induced control of cytosolic free calcium in pituitary tumour cells Br J Pharmacol 129 2000 471 484
54. G. Nowak Protein kinase C-alpha and ERK1/2 mediate mitochondrial dysfunction, decreases in active Na + transport, and cisplatin-induced apoptosis in renal cells J Biol Chem 277 2002 43377 43388
55. R. Choudhary, K.P. Mishra, and C. Subramanyam Interrelations between oxidative stress and calcineurin in the attenuation of cardiac apoptosis by eugenol Mol Cell Biochem 283 2006 115 122
56. Oyama K., Takahashi K., Sakurai K. Hydrogen peroxide induces cell cycle arrest in cardiomyoblast H9c2 cells, which is related to hypertrophy. Biol Pharm Bull 2011;34:501-6.
57. C.Y. Huang, L.C. Yang, and K.Y. Liu ZAK negatively regulates RhoGDIbeta-induced Rac1-mediated hypertrophic growth and cell migration J Biomed Sci 16 2009 56
58. T. Takahashi, T. Tang, and N.C. Lai Increased cardiac adenylyl cyclase expression is associated with increased survival after myocardial infarction Circulation 114 2006 388 396
59. Z. Sheng, K. Knowlton, J. Chen, M. Hoshijima, J.H. Brown, and K.R. Chien Cardiotrophin 1 (CT-1) inhibition of cardiac myocyte apoptosis via a mitogen-activated protein kinase-dependent pathway. Divergence from downstream CT-1 signals for myocardial cell hypertrophy J Biol Chem 272 1997 5783 5791
60. V.P. van Empel, A.T. Bertrand, L. Hofstra, H.J. Crijns, P.A. Doevendans, and L.J. De Windt Myocyte apoptosis in heart failure Cardiovasc Res 67 2005 21 29
61. K. Singh, L. Xiao, A. Remondino, D.B. Sawyer, and W.S. Colucci Adrenergic regulation of cardiac myocyte apoptosis J Cell Physiol 189 2001 257 265
62. K. Du, and M. Montminy CREB is a regulatory target for the protein kinase Akt/PKB J Biol Chem 273 1998 32377 32379
63. M.R. Montminy, and L.M. Bilezikjian Binding of a nuclear protein to the cyclic-AMP response element of the somatostatin gene Nature 328 1987 175 178
64. F.B. Mehrhof, F.U. Muller, and M.W. Bergmann In cardiomyocyte hypoxia, insulin-like growth factor-I-induced antiapoptotic signaling requires phosphatidylinositol-3-OH-kinase-dependent and mitogen-activated protein kinase-dependent activation of the transcription factor cAMP response element-binding protein Circulation 104 2001 2088 2094
65. J. Meitzen, J.I. Luoma, C.M. Stern, and P.G. Mermelstein Beta1-adrenergic receptors activate two distinct signaling pathways in striatal neurons J Neurochem 116 2011 984 995
66. O.F. Bueno, L.J. De Windt, and K.M. Tymitz The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice EMBO J 19 2000 6341 6350
67. M. Silberbach, T. Gorenc, R.E. Hershberger, P.J. Stork, P.S. Steyger, and C.T. Roberts Jr. Extracellular signal-regulated protein kinase activation is required for the anti-hypertrophic effect of atrial natriuretic factor in neonatal rat ventricular myocytes J Biol Chem 274 1999 24858 24864
68. C. Lavoie, J.F. Mercier, and A. Salahpour Beta 1/beta 2-adrenergic receptor heterodimerization regulates beta 2-adrenergic receptor internalization and ERK signaling efficacy J Biol Chem 277 2002 35402 35410
69. N. Yano, D. Suzuki, and M. Endoh Beta-adrenergic receptor mediated protection against doxorubicin-induced apoptosis in cardiomyocytes: the impact of high ambient glucose Endocrinology 149 2008 6449 6461
70. M. Zheng, S.J. Zhang, W.Z. Zhu, B. Ziman, B.K. Kobilka, and R.P. Xiao Beta 2-adrenergic receptor-induced p38 MAPK activation is mediated by protein kinase A rather than by Gi or gbeta gamma in adult mouse cardiomyocytes J Biol Chem 275 2000 40635 40640
71. Z. Xia, M. Dickens, J. Raingeaud, R.J. Davis, and M.E. Greenberg Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis Science 270 1995 1326 1331
72. P. Juo, C.J. Kuo, and S.E. Reynolds Fas activation of the p38 mitogen-activated protein kinase signalling pathway requires ICE/CED-3 family proteases Mol Cell Biol 17 1997 24 35
73. C. Morisco, D.C. Zebrowski, D.E. Vatner, S.F. Vatner, and J. Sadoshima Beta-adrenergic cardiac hypertrophy is mediated primarily by the beta(1)-subtype in the rat heart J Mol Cell Cardiol 33 2001 561 573
74. C. Communal, K. Singh, D.B. Sawyer, and W.S. Colucci Opposing effects of beta(1)- and beta(2)-adrenergic receptors on cardiac myocyte apoptosis: role of a pertussis toxin-sensitive G protein Circulation 100 1999 2210 2212
75. Y. Jiang, H. Gram, and M. Zhao Characterization of the structure and function of the fourth member of p38 group mitogen-activated protein kinases, p38delta J Biol Chem 272 1997 30122 30128
76. M.H. Cobb, and E.J. Goldsmith How MAP kinases are regulated J Biol Chem 270 1995 14843 14846
77. K.M. Pumiglia, and S.J. Decker Cell cycle arrest mediated by the MEK/mitogen-activated protein kinase pathway Proc Natl Acad Sci U S A 94 1997 448 452
78. J.M. Kyriakis, and J. Avruch Sounding the alarm: protein kinase cascades activated by stress and inflammation J Biol Chem 271 1996 24313 24316
79. Y. Wang, S. Huang, and V.P. Sah Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family J Biol Chem 273 1998 2161 2168
80. Y. Wang, B. Su, V.P. Sah, J.H. Brown, J. Han, and K.R. Chien Cardiac hypertrophy induced by mitogen-activated protein kinase kinase 7, a specific activator for c-Jun NH2-terminal kinase in ventricular muscle cells J Biol Chem 273 1998 5423 5426